ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA’s Novel Immunotherapy ISA103 in Uveal Melanoma

ISA Completes Enrolment in Randomized Double Blind Phase 2 Clinical Trial of ISA101b in HPV16 induced Oropharyngeal Cancer

Professor Melief to receive 2022 SITC Pedro J. Romero Award

ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Melief Awarded Fellowship at the Society for Immunotherapy of Cancer

ISA to Present at Business Conferences in May 2022

ISA Pharmaceuticals announces the start of clinical trial using its novel AMPLIVANT® technology

ISA to present key learnings for cancer vaccine development at the ESMO Immuno-Oncology Congress

ISA Pharmaceuticals Receives Fast Track Designation for Lead Product ISA101b

ISA Pharmaceuticals Commences Patient Treatment in Third Phase 2 Clinical Trial with the Combination of ISA101b and Libtayo® (cemiplimab)

ISA, in partnership with Erasmus MC, is awarded TKI grant and expands clinical pipeline